Neuroleptic catatonia and its relationship to psychogenic catatonia.
Neuroleptics are among those pharmacological agents that can cause a nonpsychogenic catatonic state. Neuroleptic malignant syndrome (NMS) is marked by a change in state of consciousness, ranging from withdrawal through stupor to coma. In addition, it is characterized by autonomic dysfunction, hyperthermia, mutism, and rigidity. It is included in the differential diagnosis of the catatonic syndrome. Evidence is reviewed to suggest that agents responsible for improving NMS act on the dopamine (DA) gamma aminobutyric acid (GABA) connections in the mesostriatal and mesolimbic systems and also in the hypothalamus. In addition, based on symptomatology, pathophysiology, and therapeutic mechanisms, the relationship between nonpsychogenic neuroleptic-induced catatonia and psychogenic catatonia is examined.
Fricchione
G L
GL
D014151:Anti-Anxiety Agents / Q000627:therapeutic use; D014150:Antipsychotic Agents / Q000009:adverse effects*; D001480:Basal Ganglia Diseases / Q000523:psychology*; D001569:Benzodiazepines; D001921:Brain / Q000503:physiopathology; D002389:Catatonia / Q000139:chemically induced* / Q000503:physiopathology / Q000523:psychology; D003620:Dantrolene / Q000627:therapeutic use; D003937:Diagnosis, Differential; D004298:Dopamine / Q000502:physiology; D004565:Electroconvulsive Therapy; D006801:Humans; D007031:Hypothalamus / Q000187:drug effects / Q000503:physiopathology; D008474:Medial Forebrain Bundle / Q000503:physiopathology; D009459:Neuroleptic Malignant Syndrome / Q000503:physiopathology / Q000523:psychology*; D012306:Risk
D014151:Anti-Anxiety Agents; D014150:Antipsychotic Agents; D001569:Benzodiazepines; D003620:Dantrolene; D004298:Dopamine